Topical difluprednate monotherapy for uveitic macular edema

详细信息    查看全文

• 作者：Richard J. Symes ; BSc (Hons) FRCOphth ; FRANZCO ; Farzin Forooghian ; MD ; MSc ; FRCSC ; ^{farzin.forooghian@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Canadian Journal of Ophthalmology / Journal Canadien d'Ophtalmologie
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：51
• 期：1
• 页码：47-49
• 全文大小：389 K

文摘

To describe the use of topical difluprednate for the treatment of uveitic macular edema.

Design

Retrospective review of 3 consecutive cases of uveitic macular edema.

Methods

Patients were treated with topical difluprednate monotherapy.

Results

All patients experienced complete resolution of uveitic macular edema within 2–4 weeks. We observed a statistically significant improvement in central subfield macular thickness (p = 0.04). There was an overall improvement in visual acuity, but this result was not statistically significant (p = 0.33).

Conclusions

Topical difluprednate can be effective for uveitic macular edema. Further investigation of this therapy in prospective randomized controlled trials is warranted.